Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents

Cancer Cell

Volumn 1, Issue 4, 2002, Pages 325-337

  Johnson, Leisa ^a,c   Shen, Annie ^a   Boyle, Larry ^a   Kunich, John ^a   Pandey, Kusum ^a   Lemmon, Marilyn ^a   Hermiston, Terry ^a,e   Giedlin, Marty ^a,f   McCormick, Frank ^b   Fattaey, Ali ^a,d  

^a ONYX PHARMACEUTICALS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EXELIXIS INC   (United States)

^d ProteinPlanet   (United States)

^e BAYER AG   (Germany)

^f CERUS CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; E1A PROTEIN; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F; VIRUS DNA;

ADENOVIRUS; ARTICLE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; DNA REPLICATION; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE TARGETING; HUMAN; LIFE CYCLE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; VIRUS REPLICATION; ANIMAL; CELL CULTURE; CELL CYCLE; DEFECTIVE VIRUS; EXPERIMENTAL NEOPLASM; FIBROBLAST; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; HUMAN ADENOVIRUS; METABOLISM; MOUSE; MOUSE MUTANT; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; PROMOTER REGION; SURVIVAL RATE; XENOGRAFT;

ADENOVIRIDAE; ANIMALIA; HUMAN ADENOVIRUS;

ADENOVIRUS E1A PROTEINS; ADENOVIRUSES, HUMAN; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL CYCLE PROTEINS; DEFECTIVE VIRUSES; DNA REPLICATION; DNA, VIRAL; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; FIBROBLASTS; GENE EXPRESSION REGULATION, VIRAL; GENETIC VECTORS; HUMANS; MICE; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; PROMOTER REGIONS (GENETICS); RETINOBLASTOMA PROTEIN; SURVIVAL RATE; TRANSCRIPTION FACTORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 19044386714     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(02)00060-0     Document Type: Article

References (89)

1. Barker, D.D., and Berk, A.J. (1987). Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 156, 107-121.
2. Bartek, J., Bartkova, J., and Lukas, J. (1997). The retinoblastoma protein pathway in cell cycle control and cancer. Exp. Cell Res. 237, 1-6.
3. Bayley, S.T., and Mymryk, J.S. (1994). Adenovirus E1A proteins and transformation. Int. J. Oncol. 5, 425-444.
4. Berk, A.J. (1986). Functions of adenovirus E1A. Cancer Surv. 5, 367-387.
5. Berk, A.J., Lee, F., Harrison, T., Williams, J., and Sharp, P.A. (1979). Preearly adenovirus 5 gene product regulates synthesis of early viral messenger RNAs. Cell 17, 935-944.
6. Bischoff, J.R., Kirn, D.H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J.A., Sampson-Johannes, A., Fattaey, A., and McCormick, F. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376.
7. Brunori, M., Malerba, M., Kashiwazaki, H., and Iggo, R. (2001). Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway. J. Virol. 75, 2857-2865.
8. Chase, M., Chung, R.Y., and Chiocca, E.A. (1998). An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat. Biotechnol. 16, 444-448.
9. Chung, R.Y., Saeki, Y., and Chiocca, E.A. (1999). B-myb promoter retargeting of herpes simplex virus gamma34.5 gene- mediated virulence toward tumor and cycling cells. J. Virol. 73, 7556-7564.
10. Cress, W.D., and Nevins, J.R. (1994). Interacting domains of E2F1, DP1, and the adenovirus E4 protein. J. Virol. 68, 4213-4219.
11. Debbas, M., and White, E. (1993). Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev. 7, 546-554.
12. Doronin, K., Kuppuswamy, M., Toth, K., Tollefson, A.E., Krajcsi, P., Krougliak, V., and Wold, W.S. (2001). Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J. Virol. 75, 3314-3324.
13. Duncan, S.J., Gordon, F.C., Gregory, D.W., McPhie, J.L., Postlethwaite, R., White, R., and Willcox, H.N. (1978). Infection of mouse liver by human adenovirus type 5. J. Gen. Virol. 40, 45-61.
14. Dyson, N. (1998). The regulation of E2F by pRB-family proteins. Genes Dev. 12, 2245-2262.
15. Dyson, N., Buchkovich, K., Whyte, P., and Harlow, E. (1989). Cellular proteins that are targetted by DNA tumor viruses for transformation. Princess Takamatsu Symp. 20, 191-198.
16. Dyson, N., Guida, P., McCall, C., and Harlow, E. (1992). Adenovirus E1A makes two distinct contacts with the retinoblastoma protein. J. Virol. 66, 4606-4611.
17. Engelhardt, J.F., Ye, X., Doranz, B., and Wilson, J.M. (1994). Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. USA 91, 6196-6200.
18. Fattaey, A.R., Harlow, E., and Helin, K. (1993). Independent regions of adenovirus E1A are required for binding to and dissociation of E2F-protein complexes. Mol. Cell. Biol. 13, 7267-7277.
19. Fuerer, C., and Iggo, R. (2002). Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway. Gene Ther. 9, 270-281.
20. Fueyo, J., Gomez-Manzano, C., Alemany, R., Lee, P.S., McDonnell, T.J., Mitlianga, P., Shi, Y.X., Levin, V.A., Yung, W.K., and Kyritsis, A.P. (2000). A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19, 2-12.
21. Garrett, M.D., and Fattaey, A. (1999). CDK inhibition and cancer therapy. Curr. Opin. Genet. Dev. 9, 104-111.
22. Hallenbeck, P.L., Chang, Y.N., Hay, C., Golightly, D., Stewart, D., Lin, J., Phipps, S., and Chiang, Y.L. (1999). A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Ther. 10, 1721-1733.
23. Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57-70.
24. Harbour, J.W., and Dean, D.C. (2000). The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev. 14, 2393-2409.
25. Hawkins, L.K., and Hermiston, T. (2001a). Gene delivery from the E3 region of replicating human adenovirus: evaluation of the E3B region. Gene Ther. 8, 1142-1148.
26. Hawkins, L.K., and Hermiston, T.W. (2001 b). Gene delivery from the E3 region of replicating human adenovirus: evaluation of the ADP region. Gene Ther. 8, 1132-1141.
27. Hawkins, L.K., Johnson, L., Bauzon, M., Nye, J.A., Castro, D., Kitzes, G.A., Young, M.D., Holt, J.K., Trown, P., and Hermiston, T.W. (2001). Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K region. Gene Ther. 8, 1123-1131.
28. Heise, C., Hermiston, T., Johnson, L., Brooks, G., Sampson-Johannes, A., Williams, A., Hawkins, L., and Kirn, D. (2000). An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. 6, 1134-1139.
29. Heise, C.C., Williams, A.M., Xue, S., Propst, M., and Kirn, D.H. (1999). Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res. 59, 2623-2628.
30. Helin, K. (1998). Regulation of cell proliferation by the E2F transcription factors. Curr. Opin. Genet. Dev. 8, 28-35.
31. Helin, K., and Harlow, E. (1994). Heterodimerization of the transcription factors E2F-1 and DP-1 is required for binding to the adenovirus E4 (ORF6/7) protein. J. Virol. 68, 5027-5035.
32. Hernandez-Alcoceba, R., Pihalja, M., Wicha, M.S., and Clarke, M.F. (2000). A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors. Hum. Gene Ther. 11, 2009-2024.
33. Howe, J.A., and Bayley, S.T. (1992). Effects of AdS E1A mutant viruses on the cell cycle in relation to the binding of cellular proteins including the retinoblastoma protein and cyclin A. Virology 186, 15-24.
34. Howe, J.A., Mymryk, J.S., Egan, C., Branton, P.E., and Bayley, S.T. (1990). Retinoblastoma growth suppressor and a 300-kDa protein appear to regulate cellular DNA synthesis. Proc. Natl. Acad. Sci. USA 87, 5883-5887.
35. Johnson, D.G., Ohtani, K., and Nevins, J.R. (1994). Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev. 8, 1514-1525.
36. Johnson, D.G., and Schneider-Broussard, R. (1998). Role of E2F in cell cycle control and cancer. Front. Biosci. 3, d447-d448.
37. Jones, N., and Shenk, T. (1979). An adenovirus type 5 early gene function regulates expression of other early viral genes. Proc. Natl. Acad. Sci. USA 76, 3665-3669.
38. Khuri, F.R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I.F., Romel, L., Gore, M., Ironside, J., MacDougall, R.H., Heise, C., et al. (2000). a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6, 879-885.
39. Kirn, D. (2001). Clinical research results with dl1520 (Onyx-015), a replicationselective adenovirus for the treatment of cancer: what have we learned? Gene Ther. 8, 89-98.
40. Kirn, D., Martuza, R.L., and Zwiebel, J. (2001). Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat. Med. 7, 781-787.
41. Kleinberger, T., and Shenk, T. (1993). Adenovirus E4orf4 protein binds to protein phosphatase 2A, and the complex down regulates E1A-enhanced junB transcription. J. Virol. 67, 7556-7560.
42. Kramm, C.M., Chase, M., Herrlinger, U., Jacobs, A., Pechan, P.A., Rainov, N.G., Sena-Esteves, M., Aghi, M., Barnett, F.H., Chiocca, E.A., and Breakefield, X.O. (1997). Therapeutic efficiency and safety of a second-generation replication- conditional HSV1 vector for brain tumor gene therapy. Hum. Gene Ther. 8, 2057-2068.
43. Kurihara, T., Brough, D.E., Kovesdi, I., and Kufe, D.W. (2000). Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J. Clin. Invest. 106, 763-771.
44. Larminie, C.G., Alzuherri, H.M., Cairns, C.A., McLees, A., and White, R.J. (1998). Transcription by RNA polymerases I and III: a potential link between cell growth, protein synthesis and the retinoblastoma protein. J. Mol. Med. 76, 94-103.
45. Leng, X., Connell-Crowley, L., Goodrich, D., and Harper, J.W. (1997). S-Phase entry upon ectopic expression of G1 cyclin-dependent kinases in the absence of retinoblastoma protein phosphorylation. Curr. Biol. 7, 709-712.
46. Lowe, S.W., and Ruley, H.E. (1993). Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev. 7, 535-545.
47. McCormick, F. (2001). Cancer gene therapy: fringe or cutting edge? Nat. Reviews Cancer 1, 130-141.
48. Mineta, T., Rabkin, S.D., and Martuza, R.L. (1994). Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 54, 3963-3966.
49. Mineta, T., Rabkin, S.D., Yazaki, T., Hunter, W.D., and Martuza, R.L. (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1, 938-943.
50. Moore, M., Horikoshi, N., and Shenk, T. (1996). Oncogenic potential of the adenovirus E4orf6 protein. Proc. Natl. Acad. Sci. USA 93, 11295-11301.
51. Moran, E. (1993). DNA tumor virus transforming proteins and the cell cycle. Curr. Opin. Genet. Dev. 3, 63-70.
52. Muller, H., and Helin, K. (2000). The E2F transcription factors: key regulators of cell proliferation. Biochim. Biophys. Acta 1470, M1-M12.
53. Muller, U., Kleinberger, T., and Shenk, T. (1992). Adenovirus E4orf4 protein reduces phosphorylation of c-Fos and E1A proteins while simultaneously reducing the level of AP-1. J. Virol. 66, 5867-5878.
54. Nakamura, H., Mullen, J.T., Chandrasekhar, S., Pawlik, T.M., Yoon, S.S., and Tanabe, K.K. (2001). Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res. 61, 5447-5452.
55. Neill, S.D., and Nevins, J.R. (1991). Genetic analysis of the adenovirus E4 6/7 trans activator: interaction with E2F and induction of a stable DNA-protein complex are critical for activity. J. Virol. 65, 5364-5373.
56. Neill, S.D., Hemstrom, C., Virtanen, A., and Nevins, J.R. (1990). An adenovirus E4 gene product trans-activates E2 transcription and stimulates stable E2F binding through a direct association with E2F. Proc. Natl. Acad. Sci. USA 87, 2008-2012.
57. Nemunaitis, J., Ganly, I., Khuri, F., Arseneau, J., Kuhn, J., McCarty, T., Landers, S., Maples, P., Romel, L., Randlev, B., et al. (2000). Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 60, 6359-6366.
58. Nemunaitis, J., Cunningham, C., Buchanan, A., Blackburn, A., Edelman, G., Maples, P., Netto, G., Tong, A., Randlev, B., Olson, S., and Kirn, D. (2001a). Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther. 8, 746-759.
59. Nemunaitis, J., Khuri, F., Ganly, I., Arseneau, J., Posner, M., Vokes, E., Kuhn, J., McCarty, T., Landers, S., Blackburn, A., et al. (2001b). Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. 19, 289-298.
60. Neuman, E., Flemington, E.K., Sellers, W.R., and Kaelin, W.G., Jr. (1994). Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter. Mol. Cell. Biol. 14, 6607-6615.
61. Nevels, M., Rubenwolf, S., Spruss, T., Wolf, H., and Dobner, T. (1997). The adenovirus E4orf6 protein can promote E1A/E1B-induced focus formation by interfering with p53 tumor suppressor function. Proc. Natl. Acad. Sci. USA 94, 1206-1211.
62. O'Connor, R.J., and Hearing, P. (1994). Mutually exclusive interaction of the adenovirus E4-6/7 protein and the retinoblastoma gene product with internal domains of E2F-1 and DP-1. J. Virol. 68, 6848-6862.
63. Obert, S., O'Connor, R.J., Schmid, S., and Hearing, P. (1994). The adenovirus E4-6/7 protein transactivates the E2 promoter by inducing dimerization of a heteromeric E2F complex. Mol. Cell. Biol. 14, 1333-1346.
64. Parr, M.J., Manome, Y., Tanaka, T., Wen, P., Kufe, D.W., Kaelin, W.G., Jr., and Fine, H.A. (1997). Tumor-selective transgene expression in vivo mediated by an E2F- responsive adenoviral vector. Nat. Med. 3, 1145-1149.
65. Querido, E., Marcellus, R.C., Lai, A., Charbonneau, R., Teodoro, J.G., Ketner, G., and Branton, P.E. (1997). Regulation of p53 levels by the E1B 55-kilodalton protein and E4orf6 in adenovirus-infected cells. J. Virol. 71, 3788-3798.
66. Ramachandra, M., Rahman, A., Zou, A., Vaillancourt, M., Howe, J.A., AnteIman, D., Sugarman, B., Demers, G.W., Engler, H., Johnson, D., and Shabram, P. (2001). Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat. Biotechnol. 19, 1035-1041.
67. Rao, R.N. (1996). Targets for cancer therapy in the cell cycle pathway. Curr. Opin. Oncol. 8, 516-524.
68. Raychaudhuri, P., Bagchi, S., Neill, S.D., and Nevins, J.R. (1990). Activation of the E2F transcription factor in adenovirus-infected cells involves E1A-dependent stimulation of DNA-binding activity and induction of cooperative binding mediated by an E4 gene product. J. Virol. 64, 2702-2710.
69. Reichel, R., Neill, S.D., Kovesdi, I., Simon, M.C., Raychaudhuri, P., and Nevins, J.R. (1989). The adenovirus E4 gene, in addition to the E1A gene, is important for trans-activation of E2 transcription and for E2F activation. J. Virol. 63, 3643-3650.
70. Ries, S.J., Brandts, C.H., Chung, A.S., Biederer, C.H., Hann, B.C., Lipner, E.M., McCormick, F., and Korn, W.M. (2000). Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat. Med. 6, 1128-1133.
71. Rodriguez, R., Schuur, E.R., Lim, H.Y., Henderson, G.A., Simons, J.W., and Henderson, D.R. (1997). Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57, 2559-2563.
72. Schaley, J., O'Connor, R.J., Taylor, L.J., Bar-Sagi, D., and Hearing, P. (2000). Induction of the cellular E2F-1 promoter by the adenovirus E4-6/7 protein. J. Virol. 74, 2084-2093.
73. Shen, Y., Kitzes, G., Nye, J.A., Fattaey, A., and Hermiston, T. (2001). Analyses of single-amino-acid substitution mutants of adenovirus type 5 E1B-55K protein. J. Virol. 75, 4297-4307.
74. Sherr, C.J. (2000). The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 60, 3689-3695.
75. Steegenga, W.T., Riteco, N., Jochemsen, A.G., Fallaux, F.J., and Bos, J.L. (1998). The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells. Oncogene 16, 349-357.
76. Teodoro, J.G., and Branton, P.E. (1997). Regulation of p53-dependent apoptosis, transcriptional repression, and cell transformation by phosphorylation of the 55-kilodalton E1B protein of human adenovirus type 5. J. Virol. 71, 3620-3627.
77. Teodoro, J.G., Halliday, T., Whalen, S.G., Takayesu, D., Graham, F.L., and Branton, P.E. (1994). Phosphorylation at the carboxy terminus of the 55-kilodalton adenovirus type 5 E1B protein regulates transforming activity. J. Virol. 68, 776-786.
78. Wang, H.G., Draetta, G., and Moran, E. (1991). E1A induces phosphorylation of the retinoblastoma protein independently of direct physical association between the E1A and retinoblastoma products. Mol. Cell. Biol. 11, 4253-4265.
79. Wang, H.G., Rikitake, Y., Carter, M.C., Yaciuk, P., Abraham, S.E., Zerler, B., and Moran, E. (1993). Identification of specific adenovirus E1AN-terminal residues critical to the binding of cellular proteins and to the control of cell growth. J. Virol. 67, 476-488.
80. Weinberg, R.A. (1995). The retinoblastoma protein and cell cycle control. Cell 81, 323-330.
81. Whalen, S.G., Marcellus, R.C., Whalen, A., Ahn, N.G., Ricciardi, R.P., and Branton, P.E. (1997). Phosphorylation within the transactivation domain of adenovirus E1A protein by mitogen-activated protein kinase regulates expression of early region 4. J. Virol. 71, 3545-3553.
82. White, E. (1995). Regulation of p53-dependent apoptosis by E1A and E1B. Curr. Top. Microbiol. Immunol. 199, 34-58.
83. Whyte, P., Williamson, N.M., and Harlow, E. (1989). Cellular targets for transformation by the adenovirus E1A proteins. Cell 56, 67-75.
84. Yang, C.T., You, L., Uematsu, K., Yeh, C.C., McCormick, F., and Jablons, D.M. (2001). p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. Cancer Res. 61, 5959-5963.
85. Yang, Y., Nunes, F.A., Berencsi, K., Furth, E.E., Gonczol, E., and Wilson, J.M. (1994). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA 91, 4407-4411.
86. Yew, P.R., and Berk, A.J. (1992). Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature 357, 82-85.
87. Yew, P.R., Liu, X., and Berk, A.J. (1994). Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53. Genes Dev. 8, 190-202.
88. Yu, D.C., Chen, Y., Seng, M., Dilley, J., and Henderson, D.R. (1999a). The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. 59, 4200-4203.
89. Yu, D.C., Sakamoto, G.T., and Henderson, D.R. (1999b). Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res. 59, 1498-1504.